Dr Jorg Taubel is a medical practitioner and Managing Director of Richmond Pharmacology which he co-founded in 2001. He has worked in pharmacology for nearly 20 years and during that time he has conducted more than 400 early phase studies in patient, paediatric and healthy volunteers. His experience ranges from First Time In Man to Proof Of Concept studies. His particular interest is in cardiology, neurology, gastroenterology and bridging and Thorough QT studies.

Dr Taubel is an honorary lecturer at St George's University and author of 35 publications in scientific journals. He has been a speaker at numerous international meetings and workshops in Europe, US and Japan.

He has actively participated in the consultation process regarding the implementation of the MHRA Phase I Accreditation scheme, which ultimately has lead to Richmond Pharmacology being the first CRO in the UK to obtain standard and supplementary accreditation for two clinical trials units in two NHS hospitals in London.

He is a member of the (British) Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI), the Japanese Society of Clinical Pharmacology and Therapeutics, the Deutsche Gesellschaft Fur Pharmazeutische Medizin Ev. (DGPharMed), the Arbeitsgemeinschaft Fur angewandte Humanpharmakologie (AGAH), the Royal Society of Medicine, the British Association for Pharmaceutical Physicians, the Institute of Directors (IOD), London. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom.

Dr Taubel, has over a number of years been an advocate of a standardised system to monitor over-volunteering for clinical trials. He has worked on the development on the National Volunteer Register, the precursor to the ICTVAS system, in a bid to minimise over-volunteering for clinical trials in the UK. Dr Taubel has had extensive consultation with the ABPI and several organisations offering over volunteering systems, in a bid to unify the process and ensure that any system that is used works across boarders and in an efficient manner. His unrivalled experience of early phase clinical trials is an enormous asset in the development of such a system that will meet the real needs, in particular those relating to the safety of volunteers, the quality of data and the financial implications of rolling out such a system.